https://doi.org/10.55788/ab47d13d
Dr Bradley Petek (Oregon Health and Science University, OR, USA) and co-investigators conducted a study to explore the incidence and causes of SCD among National Collegiate Athletic Association (NCAA) athletes [1]. The retrospective/prospective cohort study ran for 20 years (from 2002 through 2022) and registered over 9 million years of athletic participation.
Over those 20 years, 1,102 athletes died and 143 of these cases were reported as SCDs. The average age of those who died due to SCD was 20 years, 83% of them were men, 59% were White, and 36% were Black. Also, most SCD cases were division 1 athletes (45%), whereas 29% and 26% of the SCD cases were participating in division 2 and 3, respectively. In terms of sports, the highest absolute numbers of SCD cases were seen among American football players (30%), basketball players (25%), and track-and-field athletes (13%).
The overall incidence of SCD was 1 case in 63,682 athlete-years. The risk of SCD appeared to be higher among men, with 1 case in 43,348 athlete-years. This risk was 1 case in 164,504 athlete-years among women. Furthermore, the incidence of SCD was higher among Black athletes than among White athletes, with 1 case per 27,217 athlete-years and 1 case per 74,581 athlete-years, respectively. Next, division 1 and 2 athletes may be at higher risk, with approximately 1 case of SCD per 50,000 athlete-years compared with 1 case in 95,313 athlete-years in division 3 athletes. The highest rates were found among basketball players (1 per 19,164 athlete-years) and American football players (1 per 31,743 athlete-years).
“It becomes even more interesting when we look at the individual levels,” expressed Dr Petek. The incidence of SCD was 1 per 5,848 athlete-years among division 1 basketball players who were men and White and 1 per 7,696 athlete-years among division 1 basketball players who were men and Black. Among women athletes, the highest incidence rates were observed among division 2 track-and-field athletes who were Black (1 per 24,942 athlete-years) and division 2 basketball players who were Black (1 per 30,880 athlete-years). “When we looked at SCD over the 20-year timeframe, there was a decrease in SCD with a 5-year IRR of 0.71 (95% CI 0.61–0.82),” noted Dr Petek. He further outlined that autopsy-negative sudden unexplained death (19.5%), idiopathic left ventricular hypertrophy/possible cardiomyopathy (16.9%), and hypertrophic cardiomyopathy (12.7%) were the most common causes of SCD. Finally, Dr Petek mentioned the exertional status at the time of SCD for the various causes of SCD (see Figure).
Figure: Exertional status at the time of SCD [1]
AN-SUD, autopsy-negative sudden unexplained death; CM, cardiomyopathy; NOS, nitric oxide synthases; SCD, sudden cardiac death.
“Continual efforts to improve cardiopulmonary resuscitation training, AED access, emergency action planning, and pre-participation cardiovascular screening are imperative to improve outcomes,” Dr Petek concluded.
- Petek B, et al. Incidence and causes of sudden cardiac death in NCAA athletes: a 20-year study. FS06, AHA Scientific Sessions 2023, 11–13 November, Philadelphia, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Encouraging data for lepodisiran as Lp(a) lowering therapy Next Article
Jewel IDE: High compliance rates for novel patch wearable cardioverter defibrillator »
« Encouraging data for lepodisiran as Lp(a) lowering therapy Next Article
Jewel IDE: High compliance rates for novel patch wearable cardioverter defibrillator »
Table of Contents: AHA 2023
Featured articles
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Hot Topics in CAD/PAD
MINT: Liberal or restrictive transfusion strategy in MI with anaemia?
ORBITA-2 confirms PCI effective for symptom relief in patients with stable angina
Nicotinamide riboside shows promising trend for walking function in PAD
Pemafibrate reduces microvascular complications of PAD and T2D
Dapagliflozin improves cardiometabolic outcomes in myocardial infarction
Optimising Hypertension Outcomes
Edoxaban versus warfarin in chronic thromboembolic pulmonary hypertension
Sodium intake and blood pressure: new insights
Post-partum intervention lowers BP after hypertensive pregnancy
Biannual zilebesiran associated with substantial BP reductions
Future of Lipid-Lowering Therapies
Encouraging data for lepodisiran as Lp(a) lowering therapy
Gene editing may change the treatment landscape of hypercholesterolaemia
REPRIEVE: Mechanisms behind MACE reduction in HIV population on pitavastatin
Recaticimab may offer a solution for uncontrolled hypercholesterolaemia
Atrial Fibrillation and Sudden Cardiac Death
Abelacimab substantially lowers bleeding risk compared with rivaroxaban
Liraglutide may improve post-ablation outcomes in obese patients with AF
Single or dual cardioversion in patients with obesity and AF?
NOAH-AFNET 6: Does the duration of AHRE influence response to edoxaban?
ARTESIA: How useful is anticoagulation in subclinical AF?
Jewel IDE: High compliance rates for novel patch wearable cardioverter defibrillator
Sudden cardiac death in athletes: incidence, causes, and trends over 20 years
Miscellaneous Trials
Successful results for semaglutide in the highly anticipated SELECT trial
Can a walking intervention improve functional status and quality of life in HFrEF?
Head-to-head: Surgical embolectomy versus ultrasound-assisted thrombolysis in high-risk pulmonary embolism
Related Articles
November 8, 2021
Increased risk of cerebral venous thrombosis in COVID-19
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com